MedTrace Logo

REducing Sympathetic Activity Through Ultrasound-based Renal deneRvation in Excessive Cardiovascular Risk populaTions.

NCT05703620 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2023-01-30

No results posted yet for this study

Summary

The is a non-randomized pilot trial, open-label evaluation of the physiologic response of native kidney denervation using the Paradise denervation system in CKD, End Stage Renal Disease (ESRD), and Heart failure (HF)

Conditions

Interventions

DEVICE

Renal Denervation

All eligible participants receive ultrasound based renal denervation to both kidneys on all eligible vessels

Sponsors & Collaborators

  • ReCor Medical, Inc.

    collaborator INDUSTRY

  • Royal Perth Hospital

    lead OTHER

Principal Investigators

  • Markus Schlaich · Royal Perth Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-08
Primary Completion
2025-05-18
Completion
2026-05-18

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05703620 on ClinicalTrials.gov